---
document_datetime: 2026-02-11 14:06:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sephience.html
document_name: sephience.html
version: success
processing_time: 0.1027888
conversion_datetime: 2026-02-13 18:37:09.989853
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Academia](/en/partners-networks/academia)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One substance - one assessment](/en/partners-networks/one-substance-one-assessment-osoa-eu-collaboration-chemicals-related-data)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Sephience

# Sephience

[RSS](/en/individual-human-medicine.xml/258592)

##### Authorised

This medicine is authorised for use in the European Union

sepiapterin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sephience](#news-on)
- [More information on Sephience](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sephience is a medicine used to treat hyperphenylalaninaemia (HPA, excessive blood levels of phenylalanine) in adults and children with phenylketonuria (PKU). PKU is an inherited condition where the amino acid phenylalanine (a building block for proteins) builds up in the blood to abnormally high levels, causing problems in the nervous system.

Hyperphenylalaninaemia is rare, and Sephience was designated an 'orphan medicine' (a medicine used in rare diseases) on 20 May 2021. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2435) .

Sephience contains the active substance sepiapterin.

Expand section

Collapse section

## How is Sephience used?

Sephience can only be obtained with a prescription, and treatment must be started and supervised by a doctor experienced in the treatment of PKU.

Sephience is available as a powder to be dispersed in water or apple juice, or mixed with soft food; it is taken once a day with food.

For more information about using Sephience, see the package leaflet or contact your doctor or pharmacist.

## How does Sephience work?

In patients with PKU, an enzyme (a type of protein) called phenylalanine hydroxylase (PAH), which converts phenylalanine into another amino acid, cannot fold properly and therefore has a reduced activity. This leads to a build-up of phenylalanine in the blood, causing symptoms of the disease.

The active substance in Sephience, sepiapterin, is a version of a natural substance needed for the body to produce tetrahydrobipterin (BH4). BH4 helps PAH to convert phenylalanine. Sepiapterin reduces the level of phenylalanine in the blood in two ways: by increasing the levels of BH4 in the body, and by attaching to and stabilising PHA, increasing its activity.

## What benefits of Sephience have been shown in studies?

Sephience has been shown to reduce the levels of phenylalanine in the blood in one main study.

The first part of the study involved 157 patients with PKU who received Sephience for 14 days. Those aged at least 2 years who had a reduction of 15% or more in their phenylalanine blood levels (110 patients) were considered responsive to treatment and were involved in the second part of the study, where they received either Sephience or placebo (a dummy treatment) for 6 weeks. The main measure of effectiveness was a further change in phenylalanine blood levels in those patients who already had a 30% or more decrease in their phenylalanine blood levels in the first part of the study.

In patients who received Sephience, the reduction in phenylalanine blood levels was around 410 micromole per litre (63% reduction from the initial level) compared with around 16 micromole per litre (1.4% reduction) in those who received placebo. In addition, the study showed that patients who were known to be non-responsive to sapropterin (another medicine for hyperphenylalaninaemia) achieved a reduction in their phenylalanine blood levels of 30% or more with Sephience.

Data from an ongoing study also indicated that the benefits of treatment are maintained over time and allow patients to increase the intake of phenylalanine from their diet.

Additional data indicated that reductions in phenylalanine blood levels in patients below 2 years of age were similar to those seen in older children.

## What are the risks associated with Sephience?

For the full list of side effects and restrictions with Sephience, see the package leaflet.

The most common side effects with Sephience (which may affect more than 1 in 10 people) include upper respiratory tract infection (nose and throat infection), headache, diarrhoea and abdominal (belly) pain. Discoloured stools and hypophenylalaninaemia (low levels of phenylalanine) may also affect up to 1 in 10 people.

## Why is Sephience authorised in the EU?

Sephience has been shown to significantly decrease blood levels of phenylalanine in patients with PKU after 6 weeks of treatment compared with placebo; such reductions are expected to help control the disease and provide meaningful health benefits. The effect on phenylalanine levels have been shown to be maintained over time, and to improve patients' quality of life. Sephience also represents an alternative treatment for patients who cannot use or do not respond to existing treatments.

The safety profile of Sephience is reassuring, with no serious side effects reported.

The European Medicines Agency therefore decided that Sephience's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sephience?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sephience have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sephience are continuously monitored. Suspected side effects reported with Sephience are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sephience

Sephience received a marketing authorisation valid throughout the EU on 19 June 2025.

Sephience : EPAR - Medicine overview

Reference Number: EMA/160931/2025

English (EN) (134.6 KB - PDF)

**First published:** 28/07/2025

[View](/en/documents/overview/sephience-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-95)

български (BG) (157.78 KB - PDF)

**First published:**

28/07/2025

[View](/bg/documents/overview/sephience-epar-medicine-overview_bg.pdf)

español (ES) (134.17 KB - PDF)

**First published:**

28/07/2025

[View](/es/documents/overview/sephience-epar-medicine-overview_es.pdf)

čeština (CS) (156.39 KB - PDF)

**First published:**

28/07/2025

[View](/cs/documents/overview/sephience-epar-medicine-overview_cs.pdf)

dansk (DA) (132.89 KB - PDF)

**First published:**

28/07/2025

[View](/da/documents/overview/sephience-epar-medicine-overview_da.pdf)

Deutsch (DE) (136.08 KB - PDF)

**First published:**

28/07/2025

[View](/de/documents/overview/sephience-epar-medicine-overview_de.pdf)

eesti keel (ET) (131.69 KB - PDF)

**First published:**

28/07/2025

[View](/et/documents/overview/sephience-epar-medicine-overview_et.pdf)

ελληνικά (EL) (156.81 KB - PDF)

**First published:**

28/07/2025

[View](/el/documents/overview/sephience-epar-medicine-overview_el.pdf)

français (FR) (134.38 KB - PDF)

**First published:**

28/07/2025

[View](/fr/documents/overview/sephience-epar-medicine-overview_fr.pdf)

hrvatski (HR) (155.76 KB - PDF)

**First published:**

28/07/2025

[View](/hr/documents/overview/sephience-epar-medicine-overview_hr.pdf)

italiano (IT) (131.93 KB - PDF)

**First published:**

28/07/2025

[View](/it/documents/overview/sephience-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (153.54 KB - PDF)

**First published:**

28/07/2025

[View](/lv/documents/overview/sephience-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (155.05 KB - PDF)

**First published:**

28/07/2025

[View](/lt/documents/overview/sephience-epar-medicine-overview_lt.pdf)

magyar (HU) (157.34 KB - PDF)

**First published:**

28/07/2025

[View](/hu/documents/overview/sephience-epar-medicine-overview_hu.pdf)

Malti (MT) (158.39 KB - PDF)

**First published:**

28/07/2025

[View](/mt/documents/overview/sephience-epar-medicine-overview_mt.pdf)

Nederlands (NL) (133.18 KB - PDF)

**First published:**

28/07/2025

[View](/nl/documents/overview/sephience-epar-medicine-overview_nl.pdf)

polski (PL) (158.27 KB - PDF)

**First published:**

28/07/2025

[View](/pl/documents/overview/sephience-epar-medicine-overview_pl.pdf)

português (PT) (134.55 KB - PDF)

**First published:**

28/07/2025

[View](/pt/documents/overview/sephience-epar-medicine-overview_pt.pdf)

română (RO) (153.23 KB - PDF)

**First published:**

28/07/2025

[View](/ro/documents/overview/sephience-epar-medicine-overview_ro.pdf)

slovenčina (SK) (155.34 KB - PDF)

**First published:**

28/07/2025

[View](/sk/documents/overview/sephience-epar-medicine-overview_sk.pdf)

slovenščina (SL) (154.46 KB - PDF)

**First published:**

28/07/2025

[View](/sl/documents/overview/sephience-epar-medicine-overview_sl.pdf)

Suomi (FI) (130.89 KB - PDF)

**First published:**

28/07/2025

[View](/fi/documents/overview/sephience-epar-medicine-overview_fi.pdf)

svenska (SV) (131.97 KB - PDF)

**First published:**

28/07/2025

[View](/sv/documents/overview/sephience-epar-medicine-overview_sv.pdf)

Sephience : EPAR - Risk management plan

English (EN) (1.12 MB - PDF)

**First published:** 28/07/2025

[View](/en/documents/rmp/sephience-epar-risk-management-plan_en.pdf)

## Product information

Sephience : EPAR - Product information

English (EN) (502.06 KB - PDF)

**First published:** 28/07/2025

**Last updated:** 29/08/2025

[View](/en/documents/product-information/sephience-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-967)

български (BG) (389.54 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/bg/documents/product-information/sephience-epar-product-information_bg.pdf)

español (ES) (250.18 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/es/documents/product-information/sephience-epar-product-information_es.pdf)

čeština (CS) (359.9 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/cs/documents/product-information/sephience-epar-product-information_cs.pdf)

dansk (DA) (251.21 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/da/documents/product-information/sephience-epar-product-information_da.pdf)

Deutsch (DE) (263.66 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/de/documents/product-information/sephience-epar-product-information_de.pdf)

eesti keel (ET) (241.69 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/et/documents/product-information/sephience-epar-product-information_et.pdf)

ελληνικά (EL) (413.04 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/el/documents/product-information/sephience-epar-product-information_el.pdf)

français (FR) (249.47 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/fr/documents/product-information/sephience-epar-product-information_fr.pdf)

hrvatski (HR) (419.63 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/hr/documents/product-information/sephience-epar-product-information_hr.pdf)

íslenska (IS) (244.42 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/is/documents/product-information/sephience-epar-product-information_is.pdf)

italiano (IT) (265.68 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/it/documents/product-information/sephience-epar-product-information_it.pdf)

latviešu valoda (LV) (369.21 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/lv/documents/product-information/sephience-epar-product-information_lv.pdf)

lietuvių kalba (LT) (368.39 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/lt/documents/product-information/sephience-epar-product-information_lt.pdf)

magyar (HU) (330.47 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/hu/documents/product-information/sephience-epar-product-information_hu.pdf)

Malti (MT) (364.35 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/mt/documents/product-information/sephience-epar-product-information_mt.pdf)

Nederlands (NL) (254.77 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/nl/documents/product-information/sephience-epar-product-information_nl.pdf)

norsk (NO) (267.75 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/no/documents/product-information/sephience-epar-product-information_no.pdf)

polski (PL) (372.8 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/pl/documents/product-information/sephience-epar-product-information_pl.pdf)

português (PT) (258.81 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/pt/documents/product-information/sephience-epar-product-information_pt.pdf)

română (RO) (333.29 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/ro/documents/product-information/sephience-epar-product-information_ro.pdf)

slovenčina (SK) (368.83 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/sk/documents/product-information/sephience-epar-product-information_sk.pdf)

slovenščina (SL) (331.13 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/sl/documents/product-information/sephience-epar-product-information_sl.pdf)

Suomi (FI) (243.69 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/fi/documents/product-information/sephience-epar-product-information_fi.pdf)

svenska (SV) (240.29 KB - PDF)

**First published:**

28/07/2025

**Last updated:**

29/08/2025

[View](/sv/documents/product-information/sephience-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000290244 28/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sephience : EPAR - All authorised presentations

English (EN) (39.52 KB - PDF)

**First published:** 28/07/2025

[View](/en/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-393)

български (BG) (47.43 KB - PDF)

**First published:**

28/07/2025

[View](/bg/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_bg.pdf)

español (ES) (39.62 KB - PDF)

**First published:**

28/07/2025

[View](/es/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_es.pdf)

čeština (CS) (44.38 KB - PDF)

**First published:**

28/07/2025

[View](/cs/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (40.02 KB - PDF)

**First published:**

28/07/2025

[View](/da/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (39.2 KB - PDF)

**First published:**

28/07/2025

[View](/de/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (38.33 KB - PDF)

**First published:**

28/07/2025

[View](/et/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (44.95 KB - PDF)

**First published:**

28/07/2025

[View](/el/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_el.pdf)

français (FR) (40.06 KB - PDF)

**First published:**

28/07/2025

[View](/fr/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (43.39 KB - PDF)

**First published:**

28/07/2025

[View](/hr/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (41.84 KB - PDF)

**First published:**

28/07/2025

[View](/is/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_is.pdf)

italiano (IT) (39.21 KB - PDF)

**First published:**

28/07/2025

[View](/it/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.66 KB - PDF)

**First published:**

28/07/2025

[View](/lv/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (44.45 KB - PDF)

**First published:**

28/07/2025

[View](/lt/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (44.01 KB - PDF)

**First published:**

28/07/2025

[View](/hu/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (43.37 KB - PDF)

**First published:**

28/07/2025

[View](/mt/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (38.8 KB - PDF)

**First published:**

28/07/2025

[View](/nl/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (40.69 KB - PDF)

**First published:**

28/07/2025

[View](/no/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_no.pdf)

polski (PL) (41.82 KB - PDF)

**First published:**

28/07/2025

[View](/pl/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.76 KB - PDF)

**First published:**

28/07/2025

[View](/pt/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_pt.pdf)

română (RO) (42.29 KB - PDF)

**First published:**

28/07/2025

[View](/ro/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (44.82 KB - PDF)

**First published:**

28/07/2025

[View](/sk/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (42.22 KB - PDF)

**First published:**

28/07/2025

[View](/sl/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (37.9 KB - PDF)

**First published:**

28/07/2025

[View](/fi/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (39.31 KB - PDF)

**First published:**

28/07/2025

[View](/sv/documents/all-authorised-presentations/sephience-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sephience Active substance sepiapterin International non-proprietary name (INN) or common name sepiapterin Therapeutic area (MeSH) Phenylketonurias Anatomical therapeutic chemical (ATC) code A16A

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with phenylketonuria (PKU)

## Authorisation details

EMA product number EMEA/H/C/006331

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

PTC Therapeutics International Limited

70 Sir John Rogerson's Quay

Opinion adopted 25/04/2025 Marketing authorisation issued 19/06/2025 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sephience : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (154.2 KB - PDF)

**First published:** 05/09/2025

**Last updated:** 11/02/2026

[View](/en/documents/procedural-steps-after/sephience-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sephience-PAM-0000295271 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2426689

English (EN) (1.21 MB - PDF)

**First published:** 11/02/2026

[View](/en/documents/variation-report/sephience-pam-0000295271-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Sephience : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000157789

English (EN) (316.43 KB - PDF)

**First published:** 28/07/2025

[View](/en/documents/orphan-maintenance-report/sephience-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Sephience : EPAR - Public assessment report

Adopted

Reference Number: EMA/167549/2025

English (EN) (3.29 MB - PDF)

**First published:** 28/07/2025

[View](/en/documents/assessment-report/sephience-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sephience

Adopted

Reference Number: EMA/CHMP/132388/2025

English (EN) (131.08 KB - PDF)

**First published:** 25/04/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sephience_en.pdf)

#### News on Sephience

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2025) 25/04/2025

#### More information on Sephience

- [EU/3/21/2435 - orphan designation for treatment of hyperphenylalaninemia](/en/medicines/human/orphan-designations/eu-3-21-2435)

**This page was last updated on** 11/02/2026

## Share this page

[Back to top](#main-content)